A Stanford Medicine-led study described TCIP3, a two-headed experimental molecule that eliminated aggressive human lymphoma tumors in mice by converting a cancer growth driver into a built-in kill switch rather than using a simple inhibition strategy. The reported mechanism aims to rewire protein function inside malignant cells. For oncology drug discovery, the study adds support for “molecular glue” and reprogramming concepts—approaches that can be designed to overcome resistance driven by protein network rewiring.